日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors

索拉非尼联合吉西他滨和卡铂治疗晚期实体瘤患者的I期研究

Voogd, Daphne W M; Lucassen, Merel J J; van der Noll, Ruud; Zielhuis, Sybrand W J; Boss, David; Beijnen, Jos H; Rosing, Hilde; Tibben, Matthijs; Huitema, Alwin D R; Schellens, Jan H M; Steeghs, Neeltje

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

新型聚(ADP-核糖)聚合酶 (PARP)-1 和 PARP-2 抑制剂 14C-尼拉帕尼在晚期癌症患者中的人体质量平衡研究和代谢物分析

Lotte van Andel, Z Zhang, S Lu, V Kansra, S Agarwal, L Hughes, M M Tibben, A Gebretensae, L Lucas, M J X Hillebrand, H Rosing, J H M Schellens, J H Beijnen

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection

使用干血斑样本采集测量利什曼病患者米替福新新方法的验证和临床评估

A E Kip, H Rosing, M J X Hillebrand, S Blesson, B Mengesha, E Diro, A Hailu, J H M Schellens, J H Beijnen, T P C Dorlo

Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry

高效液相色谱-串联质谱法测定外周血单个核细胞中的米替福新

A E Kip, H Rosing, M J X Hillebrand, M M Castro, M A Gomez, J H M Schellens, J H Beijnen, T P C Dorlo